Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

PDL BioPharma Inc (NASDAQ:PDLI)

3.17
Delayed Data
As of Sep 22
 -0.10 / -3.06%
Today’s Change
1.93
Today|||52-Week Range
3.77
+49.53%
Year-to-Date
ProQR's Genetic Disorder Candidate Gets Orphan Drug Status
Sep 20 / Zacks.com - Paid Partner Content
Pluristem's Ischemia Candidate Gets Fast Track Designation
Sep 19 / Zacks.com - Paid Partner Content
Should Value Investors Consider PDL BioPharma, Inc. (PDLI) Stock?
Sep 20 / Zacks.com - Paid Partner Content
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
Sep 13 / Zacks.com - Paid Partner Content